ValiRx Plc (LON:VAL)‘s stock had its “speculative buy” rating reissued by equities research analysts at Beaufort Securities in a report released on Wednesday.
Separately, Northland Securities restated a “corporate” rating on shares of ValiRx Plc in a report on Thursday, August 11th.
ValiRx Plc (LON:VAL) opened at 6.65 on Wednesday. The company’s market cap is GBX 2.91 million. The company has a 50-day moving average of GBX 7.46 and a 200 day moving average of GBX 8.82. ValiRx Plc has a one year low of GBX 5.75 and a one year high of GBX 29.80.
ValiRx Plc Company Profile
ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.
Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with MarketBeat.com's FREE daily email newsletter.